Development of smart optical nanoagents for cancer immunotheranostics

Cancer is a complicated and dynamic system composed of tumor cells and stromal cells. These cells crosstalk with each other, which impacts the tumor progression and antitumor therapeutic responses. Tumor immunotherapy, a regimen that uses exogenous immunomodulatory agents to activate endogenous stro...

Full description

Bibliographic Details
Main Author: Xu, Cheng
Other Authors: Pu Kanyi
Format: Thesis-Doctor of Philosophy
Language:English
Published: Nanyang Technological University 2024
Subjects:
Online Access:https://hdl.handle.net/10356/179290
_version_ 1826124924151922688
author Xu, Cheng
author2 Pu Kanyi
author_facet Pu Kanyi
Xu, Cheng
author_sort Xu, Cheng
collection NTU
description Cancer is a complicated and dynamic system composed of tumor cells and stromal cells. These cells crosstalk with each other, which impacts the tumor progression and antitumor therapeutic responses. Tumor immunotherapy, a regimen that uses exogenous immunomodulatory agents to activate endogenous stromal cells of host immunity to combat tumor, has been developed since 1980s. These agents include antibodies and cytokines (such as anti-programmed death ligand 1 antibody), small molecule agents (such as toll-like receptor activator imiquimod), and live cells (such as chimeric antigen receptor-T cell). These agents either directly boost cytotoxic T cells, the main immune fighter on tumor, or improve the immunosuppressive microenvironment to assist T cells activation and maintain their potency. However, current immunotherapy has some key drawbacks such as off-target toxicity, limited patients’ response, and inappropriate therapeutic intervention. This thesis aimed to discuss nanoplatforms with rational design and precisely controlled therapeutic effects on tumor for augmented antitumor immunotherapy yet reduced normal tissue toxicity. Three different nanomedicines were sequentially developed: 1) SPNE, a nanoengager comprising second-near infrared photothermal semiconducting polymer and tumor cell/dendritic cell membrane coating; 2) ASPA, a nanoantagonist assembled by semiconducting polymer conjugated with an adenosine receptor inhibitor via thermo-labile linker; and 3) SCAN, a nanotheranostic agent made of activatable sonosensitizer, substrates, or immunomodulatory agents. Those nanoagents exert immunomodulation via two aspects: first, inducing immunogenic cell death through localized photothermal or sonodynamic therapy, thus recruiting intratumoral infiltration of immunocytes; second, regulating immunocytes functions to bolster antitumor immunocytes such as dendritic cells and T cells, or dampen pro-tumoral immunocytes such as M2-like macrophages and regulatory T cells. Owing to the local irradiation with laser or ultrasound, only tumor is damaged and to be targeted with immunocytes; moreover, prodrug designs and imaging-guided dose adjustment for immunomodulatory agents further guarantee their functions unleashed only in tumor region. These features substantially spare the normal tissue damage. Consequently, these agents achieve efficient primary and distant tumor inhibition, robust immune activation, long-lasting immunological memory, metastasis prevention, and survival extension on murine models. In summary, these strategies showcase clinical promises for cancer immunotherapy.
first_indexed 2024-10-01T06:28:19Z
format Thesis-Doctor of Philosophy
id ntu-10356/179290
institution Nanyang Technological University
language English
last_indexed 2024-10-01T06:28:19Z
publishDate 2024
publisher Nanyang Technological University
record_format dspace
spelling ntu-10356/1792902024-08-01T08:11:46Z Development of smart optical nanoagents for cancer immunotheranostics Xu, Cheng Pu Kanyi School of Chemistry, Chemical Engineering and Biotechnology kypu@ntu.edu.sg Chemistry Engineering Medicine, Health and Life Sciences Molecular imaging Photothermal therapy Cancer Afterglow imaging Cancer is a complicated and dynamic system composed of tumor cells and stromal cells. These cells crosstalk with each other, which impacts the tumor progression and antitumor therapeutic responses. Tumor immunotherapy, a regimen that uses exogenous immunomodulatory agents to activate endogenous stromal cells of host immunity to combat tumor, has been developed since 1980s. These agents include antibodies and cytokines (such as anti-programmed death ligand 1 antibody), small molecule agents (such as toll-like receptor activator imiquimod), and live cells (such as chimeric antigen receptor-T cell). These agents either directly boost cytotoxic T cells, the main immune fighter on tumor, or improve the immunosuppressive microenvironment to assist T cells activation and maintain their potency. However, current immunotherapy has some key drawbacks such as off-target toxicity, limited patients’ response, and inappropriate therapeutic intervention. This thesis aimed to discuss nanoplatforms with rational design and precisely controlled therapeutic effects on tumor for augmented antitumor immunotherapy yet reduced normal tissue toxicity. Three different nanomedicines were sequentially developed: 1) SPNE, a nanoengager comprising second-near infrared photothermal semiconducting polymer and tumor cell/dendritic cell membrane coating; 2) ASPA, a nanoantagonist assembled by semiconducting polymer conjugated with an adenosine receptor inhibitor via thermo-labile linker; and 3) SCAN, a nanotheranostic agent made of activatable sonosensitizer, substrates, or immunomodulatory agents. Those nanoagents exert immunomodulation via two aspects: first, inducing immunogenic cell death through localized photothermal or sonodynamic therapy, thus recruiting intratumoral infiltration of immunocytes; second, regulating immunocytes functions to bolster antitumor immunocytes such as dendritic cells and T cells, or dampen pro-tumoral immunocytes such as M2-like macrophages and regulatory T cells. Owing to the local irradiation with laser or ultrasound, only tumor is damaged and to be targeted with immunocytes; moreover, prodrug designs and imaging-guided dose adjustment for immunomodulatory agents further guarantee their functions unleashed only in tumor region. These features substantially spare the normal tissue damage. Consequently, these agents achieve efficient primary and distant tumor inhibition, robust immune activation, long-lasting immunological memory, metastasis prevention, and survival extension on murine models. In summary, these strategies showcase clinical promises for cancer immunotherapy. Doctor of Philosophy 2024-07-25T02:43:05Z 2024-07-25T02:43:05Z 2024 Thesis-Doctor of Philosophy Xu, C. (2024). Development of smart optical nanoagents for cancer immunotheranostics. Doctoral thesis, Nanyang Technological University, Singapore. https://hdl.handle.net/10356/179290 https://hdl.handle.net/10356/179290 10.32657/10356/179290 en This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). application/pdf Nanyang Technological University
spellingShingle Chemistry
Engineering
Medicine, Health and Life Sciences
Molecular imaging
Photothermal therapy
Cancer
Afterglow imaging
Xu, Cheng
Development of smart optical nanoagents for cancer immunotheranostics
title Development of smart optical nanoagents for cancer immunotheranostics
title_full Development of smart optical nanoagents for cancer immunotheranostics
title_fullStr Development of smart optical nanoagents for cancer immunotheranostics
title_full_unstemmed Development of smart optical nanoagents for cancer immunotheranostics
title_short Development of smart optical nanoagents for cancer immunotheranostics
title_sort development of smart optical nanoagents for cancer immunotheranostics
topic Chemistry
Engineering
Medicine, Health and Life Sciences
Molecular imaging
Photothermal therapy
Cancer
Afterglow imaging
url https://hdl.handle.net/10356/179290
work_keys_str_mv AT xucheng developmentofsmartopticalnanoagentsforcancerimmunotheranostics